Melissa Matz1, Michel P Coleman2, Milena Sant3, Maria Dolores Chirlaque4, Otto Visser5, Martin Gore6, Claudia Allemani2. 1. Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: Melissa.Matz@LSHTM.ac.uk. 2. Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK. 3. Department of Preventive and Predictive Medicine, Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Department of Epidemiology, Regional Health Council, IMIB, Arrixaca, Murcia, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Department of Health and Social Sciences, Murcia University, Murcia, Spain. 5. Department of Registration, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 6. The Royal Marsden NHS Foundation Trust, London, UK.
Abstract
OBJECTIVE: Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995-2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. RESULTS: During 2005-2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. CONCLUSIONS: The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.
OBJECTIVE:Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995-2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. RESULTS: During 2005-2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. CONCLUSIONS: The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.
Authors: Vanessa L Jacoby; Victor Y Fujimoto; Linda C Giudice; Miriam Kuppermann; A Eugene Washington Journal: Am J Obstet Gynecol Date: 2010-04-28 Impact factor: 8.661
Authors: R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod Journal: Am J Hum Genet Date: 2000-03-16 Impact factor: 11.025
Authors: Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet Journal: Gynecol Oncol Date: 2012-06-27 Impact factor: 5.482
Authors: Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt Journal: Oncologist Date: 2019-04-25
Authors: Sarah R Irvin; Elisabete Weiderpass; Frank Z Stanczyk; Louise A Brinton; Britton Trabert; Hilde Langseth; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-13 Impact factor: 4.254
Authors: Adriana Fonseca; João Lobo; Florette K Hazard; Joanna Gell; Peter K Nicholls; Robert S Weiss; Lindsay Klosterkemper; Samuel L Volchenboum; James C Nicholson; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia; Michelle Lockley; Matthew J Murray Journal: Br J Cancer Date: 2022-10-13 Impact factor: 9.075
Authors: M Bossart; H Plett; B Krämer; E Braicu; B Czogalla; M Klar; S Singer; D Mayr; A Staebler; A du Bois; S Kommoss; T Link; A Burges; F Heitz; M Grube; F Trillsch; P Harter; P Wimberger; P Buderath; A Hasenburg Journal: Arch Gynecol Obstet Date: 2022-09-21 Impact factor: 2.493
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Kristin Weeks; Charles F Lynch; Michele West; Ryan Carnahan; Michael O'Rorke; Jacob Oleson; Megan McDonald; Sherri L Stewart; Mary Charlton Journal: Gynecol Oncol Date: 2020-11-18 Impact factor: 5.482
Authors: Kristin S Weeks; Charles F Lynch; Michele M West; Ryan M Carnahan; Michael A O'Rorke; Jacob J Oleson; Megan E McDonald; Mary E Charlton Journal: Am J Clin Oncol Date: 2021-10-01 Impact factor: 2.787